NCT06119685 - IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | Biotech Hunter

Enrollment

128

Participants

Timeline

Start Date

October 25, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

December 31, 2029

Conditions

NHLMultiple MyelomaBlood CancerRefractory Non-Hodgkin LymphomaRelapsed Non-Hodgkin LymphomaRefractory Multiple MyelomaRelapsed Multiple Myeloma

Interventions

DRUG

IDP-023

NK cell therapy

DRUG

Rituximab

Anti-CD20 antibody therapy

DRUG

Daratumumab

Anti-CD38 antibody therapy

DRUG

Interleukin-2

Immune cytokine

DRUG

Cyclophosphamide

Lymphodepleting chemotherapy

DRUG

Fludarabine

Lymphodepleting chemotherapy

DRUG

Mesna

Chemoprotectant

DRUG

Isatuximab

Anti-CD38 antibody therapy

Trial Locations (12)

10065

WITHDRAWN

NYP/Weill Cornell Medical Center, New York

22031

RECRUITING

NEXT Oncology Virginia, Fairfax

27157

RECRUITING

Atrium Health Wake Forest Baptist, Winston-Salem

30322

RECRUITING

Emory University Hospital, Atlanta

32746

WITHDRAWN

Florida Cancer Specialists and Research Institute - Lake Mary Cancer Center, Lake Mary

37203

RECRUITING

SCRI Oncology Partners, Nashville

44106

RECRUITING

University Hospitals Cleveland, Cleveland

55455

RECRUITING

University of Minnesota, Minneapolis

77030

RECRUITING

University of Texas MD Anderson Cancer Center, Houston

90670

RECRUITING

Valkyrie Clinical Trials, Los Angeles

97213

WITHDRAWN

Providence Cancer Institute Franz Clinic, Portland

02903

RECRUITING

Rhode Island Hospital, Providence